Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Methods and compositions for treating immune checkpoint inhibitor associated colitis

An immune checkpoint, colitis technology with applications in molecular biology and medicine

Pending Publication Date: 2022-01-07
BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF22 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Treatment with ICIs targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1) was associated with enhanced T cell activation is associated with potent antitumor immune responses, but treatment may be associated with serious immune-related adverse events (irAEs) in some patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating immune checkpoint inhibitor associated colitis
  • Methods and compositions for treating immune checkpoint inhibitor associated colitis
  • Methods and compositions for treating immune checkpoint inhibitor associated colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0176] Example 1 Fecal microbiota transplantation in the treatment of refractory immune checkpoint inhibitor-associated colitis

[0177] The inventors report the first case series of successful treatment of immune checkpoint inhibitor (ICI)-associated colitis with fecal microbiota transplantation, reconstitution of the gut microbiome and a relative increase in the proportion of regulatory T cells within the colonic mucosa. These preliminary data provide evidence that modulating the gut microbiome can eliminate ICI-associated colitis.

[0178] The inventors sought to determine the impact of treatment with FMT from healthy donors in patients with refractory ICI-associated colitis and enrolled two patients in this regimen between June 2017 and January 2018 (CIND17-0036, CIND17-0058). The clinical course of the two patients was image 3 -5 for further details. The first patient, a 50-year-old woman with high-grade metastatic urothelial carcinoma refractory to standard chemother...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described herein are methods and compositions for treating immune checkpoint inhibitor (ICI)-associated colitis in a subject comprising administering fecal matter from a healthy donor to the subject. Further aspects of the disclosure relate to a method of treating immune checkpoint inhibitor (ICI)-associated colitis in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Escherichia, Akkermansia, Bacteroides, Lachnospiraceae, Blautia, Tyzzerella, Bifidobacterium, Streptococcus, Colinsella, and Fusicatenibacter.

Description

[0001] Related Application Cross Reference [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 793,085, filed January 16, 2019, the entire contents of which are hereby incorporated by reference. [0003] Statement of Government Support [0004] This invention was made with Government support under Numbers CA219896 and HL124112 awarded by the National Institutes of Health. The government has certain rights in this invention. [0005] Background of the invention 1. Technical field [0006] The present invention relates to the fields of molecular biology and medicine. 2. Background technology [0007] Immunotherapy has transformed the field of oncology, improving long-term survival for patients with multiple cancer types. Treatment with ICIs targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1) was associated with enhanced T cell activation ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/741A61K35/745A61K35/744A61P1/00A61P29/00A23L33/135A23L2/38
CPCA61K35/37A23L33/135A61K35/741Y02A50/30A61P37/02
Inventor 詹尼弗·A·沃戈王莺红罗伯特·珍克
Owner BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com